HomeCompareCHGCY vs MRK

CHGCY vs MRK: Dividend Comparison 2026

CHGCY yields 2.99% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHGCY wins by $405.77M in total portfolio value
10 years
CHGCY
CHGCY
● Live price
2.99%
Share price
$27.52
Annual div
$0.82
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$405.82M
Annual income
$381,294,826.82
Full CHGCY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CHGCY vs MRK

📍 CHGCY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHGCYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHGCY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHGCY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHGCY
Annual income on $10K today (after 15% tax)
$253.82/yr
After 10yr DRIP, annual income (after tax)
$324,100,602.80/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CHGCY beats the other by $324,092,274.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHGCY + MRK for your $10,000?

CHGCY: 50%MRK: 50%
100% MRK50/50100% CHGCY
Portfolio after 10yr
$202.94M
Annual income
$190,652,312.48/yr
Blended yield
93.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CHGCY
No analyst data
Altman Z
22.5
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHGCY buys
9
MRK buys
0
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$CHGCY▼ Sell$1,001 - $15,0002025-04-09
Josh Gottheimer🏢 House$CHGCY▼ Sell$1,001 - $15,0002024-06-21
Josh Gottheimer🏢 House$CHGCY▼ Sell$1,001 - $15,0002024-04-04
Josh Gottheimer🏢 House$CHGCY▲ Buy$1,001 - $15,0002023-08-18
Daniel Goldman🏢 House$CHGCY▼ Sell$1,001 - $15,0002023-07-10
Daniel Goldman🏢 House$CHGCY▼ Sell$15,001 - $50,0002023-03-31
Daniel Goldman🏢 House$CHGCY▲ Buy$1,001 - $15,0002023-02-27
Peter Meijer🏢 House$CHGCY▼ Sell$15,001 - $50,0002021-02-17
Greg Gianforte🏢 House$CHGCY▼ Sell$50,001 - $100,0002020-04-14
Josh Gottheimer🏢 House$CHGCY▼ Sell$1,001 - $15,0002020-04-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHGCYMRK
Forward yield2.99%2.76%
Annual dividend / share$0.82$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$405.82M$56.8K
Annual income after 10y$381,294,826.82$9,798.13
Total dividends collected$404.01M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHGCY vs MRK ($10,000, DRIP)

YearCHGCY PortfolioCHGCY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,297$597.22$11,206$366.19+$91.00CHGCY
2$13,349$1,261.10$12,650$502.35+$699.00CHGCY
3$17,069$2,785.33$14,407$694.19+$2.7KCHGCY
4$24,921$6,656.96$16,585$967.82+$8.3KCHGCY
5$44,832$18,166.72$19,342$1,363.89+$25.5KCHGCY
6$109,057$61,087.10$22,913$1,947.19+$86.1KCHGCY
7$394,447$277,755.94$27,662$2,823.89+$366.8KCHGCY
8$2,299,836$1,877,777.60$34,159$4,173.35+$2.27MCHGCY
9$22,925,198$20,464,373.86$43,337$6,308.80+$22.88MCHGCY
10$405,824,789$381,294,826.82$56,776$9,798.13+$405.77MCHGCY

CHGCY vs MRK: Complete Analysis 2026

CHGCYStock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Full CHGCY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CHGCY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHGCY vs SCHDCHGCY vs JEPICHGCY vs OCHGCY vs KOCHGCY vs MAINCHGCY vs JNJCHGCY vs ABBVCHGCY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.